Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

June 29, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Hepatic NeoplasmHepatic Cancer
Interventions
DRUG

Intravenous esketamine using Dixon's up-and-down sequential method

Using Dixon's up-and-down sequential method, esketamine will be titrated intravenously from an initial 0.3 mg∙kg-1 dose with 0.02 mg∙kg-1 adjustments based on intraprocedural responses to pain (Positive: purposeful somatic movement or the complaint of pain; Negative: no movement or no complaint of pain). The titration sequence will continue until six crossover inflection points are observed.

DRUG

Intravenous the dose of esketamine ED95

The intervention group will be injected with the dose of esketamine ED95.

DRUG

Intravenous fentanyl 1 μg∙kg-1

The control group will be injected with fentanyl 1 μg∙kg-1.

Trial Locations (1)

361000

Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, China, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER